Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.The company offers complex products at affordable prices, serving patients with innovative respiratory drugdevice combinations, complex formulations and a wide array of capabilities across injectables, oral solids and inhalation therapies. The company strategically leverages opportunities while managing risks.

Cipla major competitors are Torrent Pharma, Dr. Reddy's Lab, Mankind Pharma, Zydus Lifesciences, Lupin, Abbott India, Alkem Laboratories.
Market Cap of Cipla is ₹1,28,239 Crs.
While the median market cap of its peers are ₹99,683 Crs.

Cipla seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.